Bausch Health R&D program developed Xifaxan to treat Irritable bowel syndrome with diarrhea (IBS-D)

Bausch Health Companies

Solutions - R&D

3: Good Health and Well-being3: Good Health and Well-being
Written by
2021-09-13 - Impact Analyst Oyelakin M. Jan 16th, 2024
Reviewed by

Research and development (R&D) investments are crucial to developing diagnostics, drugs, and vaccines that will improve and save people's lives and enhance health security1. Irritable bowel syndrome with diarrhoea (IBS-D) is a type of Irritable bo...

Register to read the full analysis —or— Upgrade to access more features

Comments

There is no comment yet.

#solutions #R&D #medicine #cure

Actual Direct Impact

Assess the impact materiality of this Topic for Bausch Health Companies

How negative/positive is the impact of Bausch Health Companies for this Topic?

How would you rate the severity of this impact?

Scale (how grave the impact is)

Scope (how widespread the impact is)

Irremediability/Persistence (how difficult it is to counteract the impact)

Share this Analysis

Bausch Health Companies

Solutions - R&D

3: Good Health and Well-being3: Good Health and Well-being
Written by
2021-09-13 - Impact Analyst Oyelakin M. Jan 16th, 2024
Reviewed by

Keen to rectify an issue with this analysis?